Screener
CG Oncology CGON G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating costs and expenses | ||||
| Cost of sales | 3,925 | — | 6,887 | — |
| Research and development | 54,657 | 31,331 | 98,387 | 58,799 |
| General and administrative | 28,976 | 17,410 | 49,756 | 32,198 |
| Total operating costs and expenses | 87,558 | 48,741 | 155,030 | 90,997 |
| Loss from operations | (86,401) | (48,741) | (152,790) | (90,945) |
| Other income (expense), net | ||||
| Interest income, net | 7,329 | 7,319 | 13,617 | 15,066 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's G&A?
- CG Oncology (CGON) reported G&A of $28.98M in Q2 2026.
- How has CG Oncology's G&A changed year-over-year?
- CG Oncology's G&A increased by 66.4% year-over-year, from $17.41M to $28.98M.
- What is the long-term trend for CG Oncology's G&A?
- Over 2 years (2023 to 2025), CG Oncology's G&A has grown at a 172.5% compound annual growth rate (CAGR), from $9.9M to $73.53M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about CG Oncology's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude